Hepatotoxicity Observed in Clinical Trials of Aplaviroc (GW873140)

Aplaviroc (APL) was a new CCR5 antagonist that was investigated in two dose-ranging studies with antiretroviral therapy-naïve, human immunodeficiency virus-infected adults: ASCENT, in which 147 subjects were randomized 2:2:1 to receive zidovudine-lamivudine (ZDV-3TC) plus APL 600 mg twice a day (BID...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Nichols, W. G., Steel, H. M., Bonny, T., Adkison, K., Curtis, L., Millard, J., Kabeya, K., Clumeck, N.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Microbiology (ASM) 2008
Gaiak:
Antiviral Agents
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2258506/
https://ncbi.nlm.nih.gov/pubmed/18070967
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00821-07
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak